Fig. 1Correlation analysis showing the association between bone mineral density and serum dipeptidyl peptidase 4/CD26 (DPP-4) activity levels in obese postmenopausal women (n=52). BMD, bone mineral density.
Table 1Baseline Clinical Characteristics of the Study Subjects (n=124)
![enm-31-93-i001.jpg]()
Variable |
Total |
Non-obese group |
Obese group |
P valuea
|
Number |
124 |
72 |
52 |
|
Age, yr |
59.9±7.1 |
59.6±7.4 |
60.2±6.7 |
0.641 |
Body mass index, kg/m2
|
24.4±2.8 |
22.4±1.5 |
27.1±2.0 |
<0.001 |
Systolic blood pressure, mm Hg |
123.9±16.0 |
120.2±15.2 |
128.8±16.0 |
0.003 |
Diastolic blood pressure, mm Hg |
75.8±10.5 |
72.5±9.6 |
80.0±10.3 |
<0.001 |
Age at menopause, yr |
50.8±3.6 |
51.0±3.3 |
50.5±4.0 |
0.455 |
No. of years since menopause |
9.1±7.6 |
8.7±7.9 |
9.7±7.2 |
0.430 |
Serum DPP-4 activity, ng/mL |
616.7±127.4 |
623.6±128.3 |
607.1±126.7 |
0.479 |
Calcium, mg/dL |
9.5±0.3 |
9.5±0.3 |
9.5±0.3 |
0.985 |
Phosphate, mg/dL |
3.8±0.5 |
3.9±0.5 |
3.8±0.5 |
0.289 |
Albumin, g/dL |
4.3±0.3 |
4.3±0.3 |
4.3±0.2 |
0.973 |
Creatinine, mg/dL |
0.6±0.1 |
0.6±0.1 |
0.6±0.1 |
0.835 |
Osteocalcin, ng/mL |
12.6±2.7 |
12.5±2.5 |
12.7±3.1 |
0.676 |
C-telopeptide, ng/mL |
0.78±0.36 |
0.80±0.42 |
0.75±0.26 |
0.378 |
Intact PTH, pg/mL |
0.092±0.050 |
0.098±0.059 |
0.084±0.032 |
0.108 |
25-Vitamin D3, ng/mL |
6.1±3.3 |
6.3±3.4 |
5.8±3.2 |
0.440 |
BMD (g/cm2) by DXA |
|
|
|
|
BMD of spine |
0.993±0.150 |
0.950±0.135 |
1.053±0.151 |
<0.001 |
BMD of femoral neck |
0.081±0.107 |
0.786±0.108 |
0.823±0.103 |
0.061 |
BMD of total hip |
0.886±0.124 |
0.859±0.117 |
0.924±0.124 |
0.003 |
Total fragility fracture history |
|
|
|
|
Total fracture history |
23 (18.5) |
14 (19.4) |
9 (17.3) |
0.099 |
Spine fracture history |
1 (0.8) |
0 |
1 (1.9) |
0.311 |
Hip fracture history |
0 |
0 |
0 |
0.159 |
Table 2Correlation between Serum DPP-4 Activity and Other Variables in the Whole Study Population (n=124)
![enm-31-93-i002.jpg]()
Variable |
R
|
P value |
Age, yr |
-0.182 |
0.043 |
Body mass index, kg/m2
|
-0.030 |
0.741 |
Systolic blood pressure, mm Hg |
-0.229 |
0.001 |
Diastolic blood pressure, mm Hg |
-0.115 |
0.203 |
Corrected calcium, mg/dL |
0.256 |
0.013 |
Phosphate, mg/dL |
0.085 |
0.835 |
Creatinine, mg/dL |
-0.092 |
0.311 |
Osteocalcin, ng/mL |
0.003 |
0.975 |
C-telopeptide, ng/mL |
0.253 |
0.005 |
Intact PTH, pg/mL |
0.220 |
0.014 |
25-Vitamin D3, ng/mL |
0.171 |
0.058 |
BMD of spine, g/cm2
|
-0.076 |
0.403 |
BMD of femoral neck, g/cm2
|
0.038 |
0.676 |
BMD of total hip, g/cm2
|
0.008 |
0.933 |
Table 3Correlation between Serum DPP-4 Activity and Other Variables in Non-Obese Subjects (n=72)
![enm-31-93-i003.jpg]()
Variable |
R
|
P value |
Age, yr |
-0.177 |
0.138 |
Body mass index, kg/m2
|
0.045 |
0.707 |
Systolic blood pressure, mm Hg |
-0.094 |
0.433 |
Diastolic blood pressure, mm Hg |
0.039 |
0.744 |
Corrected calcium, mg/dL |
0.316 |
0.007 |
Phosphate, mg/dL |
0.157 |
0.189 |
Creatinine, mg/dL |
-0.051 |
0.721 |
Osteocalcin, ng/mL |
-0.087 |
0.466 |
C-telopeptide, ng/mL |
0.284 |
0.016 |
Intact PTH, pg/mL |
0.221 |
0.062 |
25-Vitamin D3, ng/mL |
0.211 |
0.076 |
BMD of spine, g/cm2
|
0.125 |
0.296 |
BMD of femoral neck, g/cm2
|
0.102 |
0.395 |
BMD of total hip, g/cm2
|
0.085 |
0.480 |
Table 4Correlation between Serum DPP-4 Activity and Other Variables in Obese Subjects (n=52)
![enm-31-93-i004.jpg]()
Variable |
R
|
P value |
Age, yr |
-0.185 |
0.190 |
Body mass index, kg/m2
|
0.028 |
0.842 |
Systolic blood pressure, mm Hg |
-0.391 |
0.004 |
Diastolic blood pressure, mm Hg |
-0.280 |
0.044 |
Corrected calcium, mg/dL |
0.102 |
0.471 |
Phosphate, mg/dL |
-0.032 |
0.824 |
Creatinine, mg/dL |
-0.051 |
0.721 |
Osteocalcin, ng/mL |
0.111 |
0.434 |
C-telopeptide, ng/mL |
0.189 |
0.179 |
Intact PTH, pg/mL |
0.223 |
0.111 |
25-Vitamin D3, ng/mL |
0.102 |
0.472 |
BMD of spine, g/cm2
|
-0.288 |
0.038 |
BMD of femoral neck, g/cm2
|
-0.027 |
0.847 |
BMD of total hip, g/cm2
|
-0.053 |
0.708 |